Bayer’s Nexavar meets goal in thyroid cancer trial

FRANKFURT (Reuters) – German drugmaker Bayer said its cancer treatment Nexavar reached a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage clinical trial. The company said on Thursday it planned to submit data from the trial in the coming months in a bid to win regulatory approval to sell Nexavar as a treatment for radioactive iodine (RAI) refractory differentiated thyroid cancer. It would present a detailed analysis of the study, in which 417 patients took part, at an upcoming medical meeting, it added, without providing details. …